Opportunity Information: Apply for RFA NS 13 003
Apply for RFA NS 13 003
- The National Institutes of Health in the education environment health income security and social services sector is offering a public funding opportunity titled "NIH Blueprint for Neuroscience Research Grand Challenge Discovering Novel Drugs for Disorders of the Nervous System (U01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.113 Environmental Health 93.121 Oral Diseases and Disorders Research 93.173 Research Related to Deafness and Communication Disorders 93.213 Research and Training in Complementary and Integrative Health 93.242 Mental Health Research Grants 93.273 Alcohol Research Programs 93.279 Drug Abuse and Addiction Research Programs 93.286 Discovery and Applied Research for Technological Innovations to Improve Human Health 93.350 National Center for Advancing Translational Sciences 93.361 Nursing Research 93.853 Extramural Research Programs in the Neurosciences and Neurological Disorders 93.859 Biomedical Research and Research Training 93.865 Child Health and Human Development Extramural Research 93.866 Aging Research 93.867 Vision Research.
- This funding opportunity was created on Apr 19, 2012 and posted on Feb 21, 2012.
- Applicants must submit their applications by Oct 8, 2012. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Private institutions of higher education State governments Special district governments Public and State controlled institutions of higher education Public housing authorities/Indian housing authorities Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Independent school districts Small businesses For profit organizations other than small businesses County governments Native American tribal organizations (other than Federally recognized tribal governments) City or township governments Native American tribal governments (Federally recognized) Others (see text field entitled Additional Information on Eligibility for clarification).
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession Non domestic (non U.S.) Entities (Foreign Institutions) are eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The NIH Blueprint for Neuroscience Research Grand Challenge: Discovering Novel Drugs for Disorders of the Nervous System (U01) (Funding Opportunity Number RFA-NS-13-003) is a government grant opportunity designed to help move promising small-molecule neuroscience and psychiatry drug leads closer to the clinic by pairing academic or other non-pharma investigators with a centralized, "virtual pharma" development network. The core idea is to support researchers who already have (1) a credible disease-relevant assay or model in their own lab and (2) a small-molecule compound series with signs of therapeutic potential for disorders of the nervous system or psychiatric conditions, but where the program is not yet ready for clinical testing. NIH is essentially offering a path to bridge the common gap between early discovery hits/leads and the expensive, specialized preclinical-to-clinical work needed to reach an Investigational New Drug (IND) stage and eventually first-in-human testing.
The award uses a U01 cooperative agreement mechanism, meaning this is not a standard investigator-initiated grant with minimal agency involvement; instead, it is structured as an active collaboration where NIH and its contracted partners play a substantial role in steering and executing parts of the development plan. Awardees receive two major forms of support. First, they receive funding to conduct biological testing of compound analogs in their own laboratory using their established disease assays and models, which is often where deep disease expertise and specialized model systems live. Second, and unusually valuable for academic settings, they receive access at no cost to contracted drug discovery and development services that are typically difficult to obtain without industry backing. These services include medicinal chemistry optimization (to improve potency, selectivity, and drug-like properties), IND-directed pharmacology and toxicology (the kinds of studies regulators expect before human dosing), and support that extends as far as Phase I clinical testing. In practice, this structure is meant to help transform an interesting research compound into a development-ready candidate by iterating chemistry, testing improved analogs, and generating the formal preclinical package needed to justify clinical entry.
The opportunity is broad in scope across nervous system and psychiatric disorders rather than limited to a single disease area, consistent with the NIH Blueprint approach of tackling cross-cutting challenges in neuroscience. It also aligns with translational goals: applicants are expected to come in with more than a theoretical target hypothesis. The FOA is aimed at projects where a small-molecule starting point already exists and can be advanced through systematic optimization and rigorous testing. The NIH emphasis on compound analog testing in the investigator's lab suggests the program expects active feedback loops between medicinal chemistry and biological readouts, using disease-relevant assays to guide decision-making toward a more viable therapeutic candidate.
Eligibility is expansive and includes a wide range of domestic and international organizations. Eligible applicants include public and private institutions of higher education, nonprofits (including both 501(c)(3) and non-501(c)(3) organizations), small businesses, for-profit organizations (including those other than small businesses), and multiple levels of government entities (state, county, city/township, special districts), as well as tribal governments and tribal organizations. The FOA explicitly allows non-U.S. entities (foreign institutions) to apply, permits non-U.S. components of U.S. organizations, and allows foreign components as defined by NIH policy. It also names several institution types as eligible, such as HBCUs, Hispanic-serving institutions, tribally controlled colleges and universities, Alaska Native and Native Hawaiian Serving Institutions, faith-based or community-based organizations, regional organizations, and U.S. territories or possessions. There is no cost sharing or matching requirement, which reduces barriers for applicants who may not have discretionary funds to contribute.
Administratively, the opportunity was posted February 21, 2012, with an archive date of November 8, 2012. The original closing date was June 8, 2012, and the current closing date listed is October 8, 2012, indicating the solicitation remained open long enough to allow additional submissions beyond the initial deadline window. The sponsoring agency is the National Institutes of Health, and the announcement is tied to multiple CFDA program areas spanning environmental health, mental health, alcohol and drug abuse research, neurological disorders, aging, vision, nursing research, translational sciences, and other biomedical research programs, reflecting the cross-institute nature of the Blueprint initiative.
Overall, this FOA is best understood as a translational accelerator for small-molecule neurotherapeutics: it targets investigators who have already generated promising early evidence but need industry-grade capabilities (medicinal chemistry, regulated toxicology, and early clinical execution) to overcome the high technical and financial barriers between academic discovery and a clinically testable drug candidate. The official announcement and full details were made available through the NIH grants guide at http://grants.nih.gov/grants/guide/rfa-files/RFA-NS-13-003.html, and technical access issues were directed to the NIH Office of Extramural Research (OER) webmaster contact listed in the notice.
Frequently Asked Questions (FAQs)
What is this grant opportunity?
The NIH Blueprint for Neuroscience Research Grand Challenge: Discovering Novel Drugs for Disorders of the Nervous System (U01) is a government funding opportunity (Funding Opportunity Number RFA-NS-13-003) intended to move promising small-molecule neuroscience and psychiatry drug leads closer to clinical testing by connecting non-pharma investigators with a centralized, "virtual pharma" development network.
What is the main goal of RFA-NS-13-003?
The goal is to bridge the gap between early discovery (hits/leads) and the expensive, specialized work needed to reach an Investigational New Drug (IND) stage and eventually first-in-human studies. The program is designed to help transform an interesting research compound into a development-ready candidate through iterative optimization and rigorous testing.
What types of projects does this FOA aim to support?
This FOA is aimed at translational projects where a small-molecule starting point already exists and can be advanced through systematic optimization and testing. Applicants are expected to bring more than a theoretical target hypothesis and should already have credible early evidence supporting therapeutic potential.
What must investigators already have in hand to be a good fit?
Based on the FOA description, the program is intended for investigators who already have (1) a credible, disease-relevant assay or model established in their lab and (2) a small-molecule compound series that shows signs of therapeutic potential for a nervous system disorder or psychiatric condition, but is not yet ready for clinical testing.
Is this opportunity limited to a single disease area?
No. The scope is broad across disorders of the nervous system and psychiatric conditions, consistent with the NIH Blueprint approach to cross-cutting challenges in neuroscience rather than focusing on a single disease.
What award mechanism is used?
The FOA uses the U01 cooperative agreement mechanism.
What does a U01 cooperative agreement mean in practice?
It means this is not a standard investigator-initiated grant with minimal agency involvement. It is structured as an active collaboration in which NIH and its contracted partners play a substantial role in steering and executing parts of the development plan.
What kinds of support do awardees receive?
Awardees receive two major forms of support: (1) funding to conduct biological testing of compound analogs in the investigator's own lab using established disease assays and models, and (2) access at no cost to contracted drug discovery and development services that are often difficult for academic groups to obtain without industry backing.
What drug development services are provided at no cost through the program?
The FOA description lists access to contracted services including medicinal chemistry optimization (to improve potency, selectivity, and drug-like properties), IND-directed pharmacology and toxicology (studies typically expected by regulators prior to human dosing), and support that can extend as far as Phase I clinical testing.
Does the investigator still perform work in their own lab?
Yes. A key element described is funding for biological testing of compound analogs in the investigator's lab using their disease-relevant assays and models, where deep disease expertise and specialized model systems often reside.
How does the program move a compound toward IND readiness?
The program is described as supporting iterative cycles where medicinal chemistry optimization produces improved analogs, the investigator performs biological testing in disease-relevant assays/models, and the overall effort generates the formal preclinical package needed to justify clinical entry (IND stage) and potentially progress to Phase I testing.
What kinds of improvements are expected from medicinal chemistry optimization?
The FOA description specifically mentions improving potency, selectivity, and drug-like properties.
What is meant by "IND-directed" pharmacology and toxicology in this context?
It refers to pharmacology and toxicology studies aligned with what regulators typically expect before a compound can be dosed in humans, supporting progression toward an IND stage.
Does this program support Phase I clinical testing?
Yes. The FOA description notes that the contracted support can extend as far as Phase I clinical testing.
Who is eligible to apply?
Eligibility is described as expansive. Eligible applicants include public and private institutions of higher education, nonprofits (including 501(c)(3) and non-501(c)(3) organizations), small businesses, for-profit organizations (including those other than small businesses), and multiple levels of government entities (state, county, city/township, special districts), as well as tribal governments and tribal organizations.
Are foreign (non-U.S.) organizations eligible?
Yes. The FOA explicitly allows non-U.S. entities (foreign institutions) to apply. It also permits non-U.S. components of U.S. organizations and allows foreign components as defined by NIH policy.
Are specific institution types explicitly included as eligible?
Yes. The FOA description names several institution types as eligible, including HBCUs, Hispanic-serving institutions, tribally controlled colleges and universities, Alaska Native and Native Hawaiian Serving Institutions, faith-based or community-based organizations, regional organizations, and U.S. territories or possessions.
Is cost sharing or matching required?
No. The FOA states there is no cost sharing or matching requirement.
Which federal agency is sponsoring this opportunity?
The sponsoring agency is the National Institutes of Health (NIH).
When was this opportunity posted and when did it close?
The opportunity was posted February 21, 2012. The archive date is November 8, 2012. The original closing date was June 8, 2012, and the current closing date listed is October 8, 2012.
Why are there two different closing dates listed?
The provided information indicates the solicitation remained open long enough to allow additional submissions beyond the initial deadline window, reflected by an original closing date (June 8, 2012) and a later current closing date (October 8, 2012).
Is this FOA associated with multiple NIH program areas?
Yes. The announcement is tied to multiple CFDA program areas spanning environmental health, mental health, alcohol and drug abuse research, neurological disorders, aging, vision, nursing research, translational sciences, and other biomedical research programs, reflecting the cross-institute nature of the NIH Blueprint initiative.
Where can applicants find the official FOA announcement?
The official announcement and full details are available through the NIH Grants Guide at http://grants.nih.gov/grants/guide/rfa-files/RFA-NS-13-003.html.
Where were technical access issues directed?
Technical access issues were directed to the NIH Office of Extramural Research (OER) webmaster contact listed in the notice.
How should this FOA be understood at a high level?
It is best described as a translational accelerator for small-molecule neurotherapeutics, targeting investigators with promising early evidence who need industry-grade capabilities (medicinal chemistry, regulated toxicology, and early clinical execution) to overcome barriers between academic discovery and a clinically testable drug candidate.
Browse more opportunities from the same category: Education Environment Health Income Security and Social Services
Next opportunity: Telemetry Flights and Water Catchments for Sonoran Pronghorn
Previous opportunity: GeoPRISMS Program
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA NS 13 003
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA NS 13 003) also looked into and applied for these:
| Funding Opportunity |
|---|
| Administrative Supplements for Health Impacts of Household Air Pollution on Womens Health and Child Survival (Admin Supp) Apply for PA 12 202 Funding Number: PA 12 202 Agency: National Institutes of Health Category: Education Environment Health Income Security and Social Services Funding Amount: Case Dependent |
| Exploratory/Developmental Bioengineering Research Grants (EBRG) R21 Apply for PA 12 284 Funding Number: PA 12 284 Agency: National Institutes of Health Category: Education Environment Health Income Security and Social Services Funding Amount: $200,000 |
| NIH Summer Research Experience Programs (R25) Apply for PAR 13 104 Funding Number: PAR 13 104 Agency: National Institutes of Health Category: Education Environment Health Income Security and Social Services Funding Amount: Case Dependent |
| Understanding and Promoting Health Literacy (R03) Apply for PAR 13 131 Funding Number: PAR 13 131 Agency: National Institutes of Health Category: Education Environment Health Income Security and Social Services Funding Amount: $50,000 |
| Understanding and Promoting Health Literacy (R21) Apply for PAR 13 132 Funding Number: PAR 13 132 Agency: National Institutes of Health Category: Education Environment Health Income Security and Social Services Funding Amount: $200,000 |
| Bioengineering Research Grants (BRG) (R01) Apply for PAR 13 137 Funding Number: PAR 13 137 Agency: National Institutes of Health Category: Education Environment Health Income Security and Social Services Funding Amount: Case Dependent |
| Development of Highly Innovative Tools and Technology for Analysis of Single Cells (SBIR) (R43/R44) Apply for PA 13 140 Funding Number: PA 13 140 Agency: National Institutes of Health Category: Education Environment Health Income Security and Social Services Funding Amount: Case Dependent |
| Chronic Inflammation and Age related Disease (R01) Apply for PAR 13 233 Funding Number: PAR 13 233 Agency: National Institutes of Health Category: Education Environment Health Income Security and Social Services Funding Amount: Case Dependent |
| NIH Small Research Grant Program (Parent R03) Apply for PA 13 304 Funding Number: PA 13 304 Agency: National Institutes of Health Category: Education Environment Health Income Security and Social Services Funding Amount: $50,000 |
| NIH Exploratory/Developmental Research Grant Program (Parent R21) Apply for PA 13 303 Funding Number: PA 13 303 Agency: National Institutes of Health Category: Education Environment Health Income Security and Social Services Funding Amount: $200,000 |
| Behavioral and Social Science Research on Understanding and Reducing Health Disparities (R21) Apply for PA 13 288 Funding Number: PA 13 288 Agency: National Institutes of Health Category: Education Environment Health Income Security and Social Services Funding Amount: $200,000 |
| Modeling Social Behavior (R01) Apply for PAR 13 374 Funding Number: PAR 13 374 Agency: National Institutes of Health Category: Education Environment Health Income Security and Social Services Funding Amount: Case Dependent |
| BRAIN Initiative Transformative Approaches for Cell Type Classification in the Brain (U01) Apply for RFA MH 14 215 Funding Number: RFA MH 14 215 Agency: National Institutes of Health Category: Education Environment Health Income Security and Social Services Funding Amount: Case Dependent |
| BRAIN Initiative New Technologies and Novel Approaches for Large Scale Recording and Modulation in the Nervous System (U01) Apply for RFA NS 14 007 Funding Number: RFA NS 14 007 Agency: National Institutes of Health Category: Education Environment Health Income Security and Social Services Funding Amount: Case Dependent |
| BRAIN Initiative Planning for Next Generation Human Brain Imaging (R24) Apply for RFA MH 14 217 Funding Number: RFA MH 14 217 Agency: National Institutes of Health Category: Education Environment Health Income Security and Social Services Funding Amount: $300,000 |
| BRAIN Initiative Optimization of Transformative Technologies for Large Scale Recording and Modulation in the Nervous System (U01) Apply for RFA NS 14 008 Funding Number: RFA NS 14 008 Agency: National Institutes of Health Category: Education Environment Health Income Security and Social Services Funding Amount: Case Dependent |
| BRAIN Initiative Development and Validation of Novel Tools to Analyze Cell Specific and Circuit Specific Processes in the Brain (U01) Apply for RFA MH 14 216 Funding Number: RFA MH 14 216 Agency: National Institutes of Health Category: Education Environment Health Income Security and Social Services Funding Amount: Case Dependent |
| BRAIN Initiative Integrated Approaches to Understanding Circuit Function in the Nervous System (U01) Apply for RFA NS 14 009 Funding Number: RFA NS 14 009 Agency: National Institutes of Health Category: Education Environment Health Income Security and Social Services Funding Amount: Case Dependent |
| Independent Scientist Award (Parent K02) Apply for PA 14 045 Funding Number: PA 14 045 Agency: National Institutes of Health Category: Education Environment Health Income Security and Social Services Funding Amount: Case Dependent |
| Bioengineering Research Partnerships (BRP) R01 Apply for PAR 14 092 Funding Number: PAR 14 092 Agency: National Institutes of Health Category: Education Environment Health Income Security and Social Services Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA NS 13 003", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.